Get the Stockscreener App
8.5323
1.67%
0.1323
Wave Life Sciences Ltd stock is traded at $8.5323, with a volume of 583.95K.
It is up +1.67% in the last 24 hours and up +28.04% over the past month.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
See More
Previous Close:
$8.40
Open:
$8.79
24h Volume:
583.95K
Relative Volume:
0.42
Market Cap:
$1.33B
Revenue:
$53.61M
Net Income/Loss:
$-142.52M
P/E Ratio:
-7.6868
EPS:
-1.11
Net Cash Flow:
$-141.83M
1W Performance:
+8.51%
1M Performance:
+28.04%
6M Performance:
-29.07%
1Y Performance:
+30.78%
1-Day Range:
$8.36
$8.88
1-Week Range:
$7.69
$8.88
52-Week Range:
$5.04
$16.73
Wave Life Sciences Ltd Stock (WVE) Company Profile
Name
Wave Life Sciences Ltd
Sector
Industry
Phone
617-949-2900
Address
7 STRAITS VIEW, SINGAPORE
Compare WVE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
WVE
Wave Life Sciences Ltd
|
8.53 | 1.31B | 53.61M | -142.52M | -141.83M | -1.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.41 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
565.98 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.58 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
596.42 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
297.70 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-16-25 | Initiated | Citigroup | Buy |
| Jun-11-25 | Resumed | Raymond James | Outperform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-08-25 | Initiated | Wedbush | Outperform |
| Feb-25-25 | Initiated | Jefferies | Buy |
| Oct-16-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-27-24 | Resumed | JP Morgan | Overweight |
| Sep-19-24 | Initiated | B. Riley Securities | Buy |
| Sep-09-24 | Initiated | JP Morgan | Overweight |
| May-15-24 | Initiated | Wells Fargo | Overweight |
| Dec-19-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-05-23 | Initiated | Raymond James | Outperform |
| May-24-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-15-20 | Resumed | H.C. Wainwright | Buy |
| Oct-23-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-31-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-01-19 | Initiated | Guggenheim | Buy |
| Jul-15-19 | Initiated | Cowen | Market Perform |
| Apr-17-19 | Reiterated | H.C. Wainwright | Buy |
| Aug-07-18 | Initiated | Stifel | Buy |
| Jul-23-18 | Initiated | H.C. Wainwright | Buy |
| Mar-19-18 | Reiterated | Mizuho | Buy |
| Feb-15-17 | Initiated | H.C. Wainwright | Buy |
| Nov-10-16 | Resumed | Leerink Partners | Outperform |
| Dec-07-15 | Initiated | JMP Securities | Mkt Outperform |
| Dec-07-15 | Initiated | Jefferies | Buy |
| Dec-07-15 | Initiated | Leerink Partners | Outperform |
| Dec-07-15 | Initiated | Sun Trust Rbsn Humphrey | Buy |
View All
Wave Life Sciences Ltd Stock (WVE) Latest News
This MongoDB Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
What are the latest earnings results for Wave Life Sciences Ltd.Maximize your returns with expert insights - jammulinksnews.com
Oppenheimer initiates Wave Life Sciences stock with Outperform rating - Investing.com Australia
What is the dividend policy of Wave Life Sciences Ltd. stockAchieve breakthrough profits with expert advice - jammulinksnews.com
How many analysts rate Wave Life Sciences Ltd. as a “Buy”Market-leading capital gains - jammulinksnews.com
What are analysts’ price targets for Wave Life Sciences Ltd. in the next 12 monthsFree Investment Portfolio Suggestions - jammulinksnews.com
When is Wave Life Sciences Ltd. stock expected to show significant growthConsistently high returns - jammulinksnews.com
What is the risk reward ratio of investing in Wave Life Sciences Ltd. stockPhenomenal trading returns - jammulinksnews.com
What makes Wave Life Sciences Ltd. stock price move sharplySmall Risk Large Return Trades - metal.it
Wave Life Sciences Ltd. Stock Analysis and ForecastSuperior profit margins - PrintWeekIndia
What risks could impact Wave Life Sciences Ltd. stock performanceConsistently exceptional gains - jammulinksnews.com
What analysts say about Wave Life Sciences Ltd. stockExplosive trading growth - PrintWeekIndia
Is Wave Life Sciences Ltd. a good long term investmentLightning-fast growth - Autocar Professional
Wave Life Sciences Second Quarter 2025 Financial Results Scheduled for July 30, 2025 - GlobeNewswire
Wave Life Sciences to Host Webcast for Q2 2025 Financial Results and Business Updates - Quiver Quantitative
Wave Life Sciences RNA Medicine Pioneer Announces Q2 2025 Earnings DateKey Updates Expected - Stock Titan
What drives Wave Life Sciences Ltd. stock priceFree Stock Selection - jammulinksnews.com
Why Wave Life Sciences Ltd. stock attracts strong analyst attentionFree Join Group - Newser
(WVE) Investment Analysis - news.stocktradersdaily.com
Wave Life Sciences Ltd.'s (NASDAQ:WVE) 27% Price Boost Is Out Of Tune With Revenues - 富途牛牛
WAVE Life Sciences (NASDAQ:WVE) Research Coverage Started at Citigroup - Defense World
Will WAVE's Q1 2025 forecast meet expectations? - AInvest
When is the best time to buy Wave Life Sciences Ltd. stockReturn Maximized Portfolio Strategy - Newser
WAVE Life Sciences Receives Buy Rating and USD 16 Price Target from Citigroup - AInvest
Wave Life Sciences’ SWOT analysis: RNA editing stock poised for breakthrough - Investing.com
Wave Life Sciences Unveils Promising Preclinical Data for Obesity Treatment WVE-007 at ADA Scientific Sessions - MSN
Jessica Chen - White & Case LLP
Breaking Down WAVE Life Sciences: 4 Analysts Share Their Views - Benzinga
Citi initiates coverage on WAVE Life Sciences stock with Buy rating - Investing.com Australia
Citi initiates coverage on WAVE Life Sciences stock with Buy rating By Investing.com - Investing.com South Africa
Wave Life Sciences Ltd Stock (WVE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.49%
1.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):